Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
XBiotech Inc (XBIT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: XBIT (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
0 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
Analysis of Past Performance
Type Stock | Historic Profit -2.47% | Avg. Invested days 25 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 85.37M USD | Price to earnings Ratio - | 1Y Target Price 18 |
Price to earnings Ratio - | 1Y Target Price 18 | ||
Volume (30-day avg) - | Beta 0.97 | 52 Weeks Range 2.50 - 8.32 | Updated Date 06/29/2025 |
52 Weeks Range 2.50 - 8.32 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.29 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -13.78% | Return on Equity (TTM) -20.53% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -77061354 | Price to Sales(TTM) 12.23 |
Enterprise Value -77061354 | Price to Sales(TTM) 12.23 | ||
Enterprise Value to Revenue 24.05 | Enterprise Value to EBITDA -1.6 | Shares Outstanding 30487700 | Shares Floating 19852696 |
Shares Outstanding 30487700 | Shares Floating 19852696 | ||
Percent Insiders 35.07 | Percent Institutions 14.92 |
Upturn AI SWOT
XBiotech Inc
Company Overview
History and Background
XBiotech Inc. (XBIT) is a biopharmaceutical company pioneering the discovery and development of True Humanu2122 antibodies for treating diseases. It was founded in 2004.
Core Business Areas
- Antibody Therapeutics: Focuses on developing antibody therapies targeting inflammatory diseases and cancer. Previously developed Bermekimab, targeting IL-1u03b1.
Leadership and Structure
The company is led by John Simard, its CEO. Details of the full organizational structure are not readily available in public domain.
Top Products and Market Share
Key Offerings
- Bermekimab (Discontinued): Previously a key asset, Bermekimab targeted IL-1u03b1 and was in development for inflammatory diseases. Development was discontinued in 2021. Competitors included companies developing other anti-inflammatory biologics.
- Other Antibody Therapies: XBiotech is actively developing new antibody therapies with undisclosed targets. Their success would rely on the novel approach in comparison to competitors such as Amgen (AMGN), Johnson & Johnson (JNJ) and AbbVie (ABBV).
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, stringent regulatory requirements, and intense competition. The antibody therapeutics market is growing significantly.
Positioning
XBiotech aims to differentiate itself with its True Humanu2122 antibody platform. However, without current late-stage assets, its positioning relies heavily on future R&D success.
Total Addressable Market (TAM)
The TAM for antibody therapeutics is substantial, estimated to be in the hundreds of billions of dollars annually. XBiotech's current positioning leaves it relying on novel discoveries to capture any substantial portion of this TAM.
Upturn SWOT Analysis
Strengths
- True Humanu2122 antibody platform
- Experienced leadership
- Proprietary technology
Weaknesses
- Lack of current revenue-generating products
- High dependence on R&D success
- Limited financial resources compared to larger competitors
Opportunities
- Potential partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Breakthrough discoveries in antibody therapeutics
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles
Competitors and Market Share
Key Competitors
- AMGN
- JNJ
- ABBV
- LLY
- MRK
Competitive Landscape
XBiotech faces significant competition from larger, established pharmaceutical companies with greater resources and existing product portfolios. XBIT needs to develop new product to compete in the landscape.
Growth Trajectory and Initiatives
Historical Growth: Historical growth was tied to the development of Bermekimab, which was discontinued.
Future Projections: Future growth depends entirely on the success of new R&D programs. Projections are highly speculative.
Recent Initiatives: Focus is on discovering and developing new antibody therapies.
Summary
XBiotech is a high-risk, high-reward biopharmaceutical company reliant on its proprietary True Humanu2122 antibody platform. The discontinuation of Bermekimab has significantly impacted its value, making future success dependent on the discovery and development of new therapies. The company needs to successfully navigate a highly competitive landscape and demonstrate the clinical efficacy of its pipeline assets to generate sustainable value. Cash management and strategic partnerships will be vital.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Industry Reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. The biopharmaceutical industry is inherently risky, and XBiotech's future performance is subject to numerous uncertainties.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About XBiotech Inc
Exchange NASDAQ | Headquaters Austin, TX, United States | ||
IPO Launch date 2015-04-15 | Founder, President, CEO & Chairman Mr. John Simard | ||
Sector Healthcare | Industry Biotechnology | Full time employees 90 | Website https://www.xbiotech.com |
Full time employees 90 | Website https://www.xbiotech.com | ||
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes true human monoclonal antibodies for treating various diseases. It develops a pipeline of product candidates targeting inflammatory and infectious diseases. The company is also developing interleukin-1 alpha therapies to various medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and general inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.